Stay updated on Pembrolizumab SBRT in TKI mRCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab SBRT in TKI mRCC Clinical Trial page.

Latest updates to the Pembrolizumab SBRT in TKI mRCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe clinical trial record is now available, describing a phase 2 study of pembrolizumab combined with SBRT for metastatic renal cell cancer. It includes the study design and eligibility details, and reports that the study is completed with an actual enrollment of four participants.SummaryDifference47%

- Check15 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the page remains an error page.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner announces updates to NIH websites and says the agency is using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page is now shown as a 403 Forbidden error, replacing the usual study details and navigation with an access-denied screen.SummaryDifference18%

Stay in the know with updates to Pembrolizumab SBRT in TKI mRCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab SBRT in TKI mRCC Clinical Trial page.